Prevención no farmacológica de la neumonía asociada a ventilación mecánica

Luis Aurelio Díaz; Mireia Llauradó; Jordi Rello; Marcos I. Restrepo

doi:10.1016/S1579-2129(10)70047-1

Prevención no farmacológica de la neumonía asociada a ventilación mecánica

Translated title of the contribution: Non-Pharmacological Prevention of Ventilator Associated Pneumonia

Luis Aurelio Díaz, Mireia Llauradó, Jordi Rello, Marcos I. Restrepo

Department of Medicine

Research output: Contribution to journal › Review article › peer-review

25 Scopus citations

Abstract

Ventilator-associated pneumonia (VAP) is the first cause of mortality due to nosocomial infections in the intensive care unit. Its incidence ranges from 9% to 67% of patients on mechanical ventilation. Risk factors are multiple and are associated with prolonged stays in hospital and intensive care units. Additional costs for each episode of VAP range from 9,000 y to 31,000 €. Thus, its prevention should be considered as a priority. This prevention could decrease associated morbidity, mortality, costs, and increase patient safety.

Translated title of the contribution	Non-Pharmacological Prevention of Ventilator Associated Pneumonia
Original language	Spanish
Pages (from-to)	188-195
Number of pages	8
Journal	Archivos de Bronconeumologia
Volume	46
Issue number	4
DOIs	https://doi.org/10.1016/S1579-2129(10)70047-1
State	Published - Apr 2010

Keywords

Artificial respiration
Cross infection
Disease prevention
Intensive care unit
Ventilator-associated pneumonia

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1016/S1579-2129(10)70047-1

Cite this

@article{22a16db0d0dd43f1887e97073bd908e7,

title = "Prevenci{\'o}n no farmacol{\'o}gica de la neumon{\'i}a asociada a ventilaci{\'o}n mec{\'a}nica",

abstract = "Ventilator-associated pneumonia (VAP) is the first cause of mortality due to nosocomial infections in the intensive care unit. Its incidence ranges from 9% to 67% of patients on mechanical ventilation. Risk factors are multiple and are associated with prolonged stays in hospital and intensive care units. Additional costs for each episode of VAP range from 9,000 y to 31,000 €. Thus, its prevention should be considered as a priority. This prevention could decrease associated morbidity, mortality, costs, and increase patient safety.",

keywords = "Artificial respiration, Cross infection, Disease prevention, Intensive care unit, Ventilator-associated pneumonia",

author = "D{\'i}az, {Luis Aurelio} and Mireia Llaurad{\'o} and Jordi Rello and Restrepo, {Marcos I.}",

note = "Funding Information: Funded in part by CibeRes and AGAUR SGR 05/520. Dr. Restrepo has a UTHSCSA and NIH grant through the CTSA (KL2 RR025766).",

year = "2010",

month = apr,

doi = "10.1016/S1579-2129(10)70047-1",

language = "Spanish",

volume = "46",

pages = "188--195",

journal = "Archivos de Bronconeumologia",

issn = "0300-2896",

publisher = "Ediciones Doyma, S.L.",

number = "4",

}

TY - JOUR

T1 - Prevención no farmacológica de la neumonía asociada a ventilación mecánica

AU - Díaz, Luis Aurelio

AU - Llauradó, Mireia

AU - Rello, Jordi

AU - Restrepo, Marcos I.

N1 - Funding Information: Funded in part by CibeRes and AGAUR SGR 05/520. Dr. Restrepo has a UTHSCSA and NIH grant through the CTSA (KL2 RR025766).

PY - 2010/4

Y1 - 2010/4

N2 - Ventilator-associated pneumonia (VAP) is the first cause of mortality due to nosocomial infections in the intensive care unit. Its incidence ranges from 9% to 67% of patients on mechanical ventilation. Risk factors are multiple and are associated with prolonged stays in hospital and intensive care units. Additional costs for each episode of VAP range from 9,000 y to 31,000 €. Thus, its prevention should be considered as a priority. This prevention could decrease associated morbidity, mortality, costs, and increase patient safety.

AB - Ventilator-associated pneumonia (VAP) is the first cause of mortality due to nosocomial infections in the intensive care unit. Its incidence ranges from 9% to 67% of patients on mechanical ventilation. Risk factors are multiple and are associated with prolonged stays in hospital and intensive care units. Additional costs for each episode of VAP range from 9,000 y to 31,000 €. Thus, its prevention should be considered as a priority. This prevention could decrease associated morbidity, mortality, costs, and increase patient safety.

KW - Artificial respiration

KW - Cross infection

KW - Disease prevention

KW - Intensive care unit

KW - Ventilator-associated pneumonia

UR - http://www.scopus.com/inward/record.url?scp=77950367608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950367608&partnerID=8YFLogxK

U2 - 10.1016/S1579-2129(10)70047-1

DO - 10.1016/S1579-2129(10)70047-1

M3 - Review article

C2 - 19819060

AN - SCOPUS:77950367608

SN - 0300-2896

VL - 46

SP - 188

EP - 195

JO - Archivos de Bronconeumologia

JF - Archivos de Bronconeumologia

IS - 4

ER -

Prevención no farmacológica de la neumonía asociada a ventilación mecánica

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this